Singapore Programme of Research to Investigate New approaches to Treatments for Tuberculosis (“SPRINT-TB”) has commenced in 2014 with a vision to become the leading international academic research programme on delivering new treatments for TB by 2018. Headed by Lead Principal Investigator Prof. Nick Paton (Department of Medicine, National University of Singapore), the programme has been awarded funding by the National Medical Research Council of Singapore (NMRC) under the Translational and Clinical Research (TCR) Flagship Grant Tier 1 scheme for an initial period of 5 years. In addition to the TCR Flagship funded projects and activities, SPRINT-TB includes a number of existing TB research projects funded by Singapore and international grant bodies that total over S$25 million.
SPRINT-TB brings together several inter-institutional research groups that will work together towards achieving the programme’s vision. A/Prof Thomas Dick’s group (Department of Microbiology, National University of Singapore) will work on identifying novel drug targets in mycobacteria, while Prof. Alex Matter’s team (Experimental Therapeutics Centre, A*STAR, Singapore) will focus on drug discovery, pre-clinical development and animal models. Programme’s clinical development theme, led by Prof. Nick Paton, will undertake TB drug clinical trials, including TRUNCATE-TB – a large phase 2/3 Asian multicentre trial for novel drug regimens in patients with drug-sensitive TB. Prof. Richard Coker (Saw Swee Hock School of Public Health, National University of Singapore) will lead treatment delivery research.
SPRINT-TB has also attracted numerous collaborators across Singapore's research institutions, Asian regional universities and hospitals, as well as academic and industry researchers in Europe and USA. The programme will be overseen by a Scientific Advisory Board comprising of invited independent experts.
SPRINT-TB brings together several inter-institutional research groups that will work together towards achieving the programme’s vision. A/Prof Thomas Dick’s group (Department of Microbiology, National University of Singapore) will work on identifying novel drug targets in mycobacteria, while Prof. Alex Matter’s team (Experimental Therapeutics Centre, A*STAR, Singapore) will focus on drug discovery, pre-clinical development and animal models. Programme’s clinical development theme, led by Prof. Nick Paton, will undertake TB drug clinical trials, including TRUNCATE-TB – a large phase 2/3 Asian multicentre trial for novel drug regimens in patients with drug-sensitive TB. Prof. Richard Coker (Saw Swee Hock School of Public Health, National University of Singapore) will lead treatment delivery research.
SPRINT-TB has also attracted numerous collaborators across Singapore's research institutions, Asian regional universities and hospitals, as well as academic and industry researchers in Europe and USA. The programme will be overseen by a Scientific Advisory Board comprising of invited independent experts.
RSS Feed
